Learn what deucravacitinib is, how selective TYK2 inhibition works, and key clinical trial results in moderate-to-severe plaque psoriasis. Discover its mechanism, benefits over traditional JAK inhibitors, and potential role as an oral alternative to biologics.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and how it differs from traditional JAK inhibitors in autoimmune diseases like plaque psoriasis, psoriatic arthritis, SLE, and IBD.